Literature DB >> 19713201

Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study.

E M Freel1, I K Tsorlalis, J D Lewsey, R Latini, A P Maggioni, S Solomon, B Pitt, J M C Connell, J J V McMurray.   

Abstract

BACKGROUND: Aldosterone has a key role in the pathophysiology of heart failure. In around 50% of such patients, aldosterone "escapes" from inhibition by drugs that interrupt the renin-angiotensin axis; such patients have a worse clinical outcome. Insulin resistance is a risk factor in heart failure and cardiovascular disease. The relation between aldosterone status and insulin sensitivity was investigated in a cohort of heart failure patients.
METHODS: 302 patients with New York Heart Association (NYHA) class II-IV heart failure on conventional therapy were randomised in the ALiskiren Observation of heart Failure Treatment study (ALOFT), designed to test the safety of a directly acting renin inhibitor. Plasma aldosterone and 24-hour urinary aldosterone excretion, as well as fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) were measured. Subjects with aldosterone escape and high urinary aldosterone were identified according to previously accepted definitions.
RESULTS: 20% of subjects demonstrated aldosterone escape and 34% had high urinary aldosterone levels. At baseline, there was a positive correlation between fasting insulin and plasma (r = 0.22 p<0.01) and urinary aldosterone(r = 0.19 p<0.03). Aldosterone escape and high urinary aldosterone subjects both demonstrated higher levels of fasting insulin (p<0.008, p<0.03), HOMA-IR (p<0.06, p<0.03) and insulin-glucose ratios (p<0.006, p<0.06) when compared to low aldosterone counterparts. All associations remained significant when adjusted for potential confounders.
CONCLUSIONS: This study demonstrates a novel direct relation between aldosterone status and insulin resistance in heart failure. This observation merits further study and may identify an additional mechanism that contributes to the adverse clinical outcome associated with aldosterone escape.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713201     DOI: 10.1136/hrt.2009.173344

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  12 in total

Review 1.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

2.  Aldosterone aggravates glucose intolerance induced by high fructose.

Authors:  Shamshad J Sherajee; Kazi Rafiq; Daisuke Nakano; Hirohito Mori; Hideki Kobara; Hirofumi Hitomi; Yoshihide Fujisawa; Hiroyuki Kobori; Tsutomu Masaki; Akira Nishiyama
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

Review 3.  Mineralocorticoid receptor antagonists and the metabolic syndrome.

Authors:  Amir Tirosh; Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 4.  Secondary diabetes mellitus due to primary aldosteronism.

Authors:  Melpomeni Moustaki; Stavroula A Paschou; Eleni C Vakali; Andromachi Vryonidou
Journal:  Endocrine       Date:  2022-08-24       Impact factor: 3.925

5.  Differential predictors of insulin resistance in nondiabetic salt-resistant and salt-sensitive subjects.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

6.  Excess aldosterone-induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat.

Authors:  Jayaraman Selvaraj; Sampath Sathish; Chinnaiyan Mayilvanan; Karundevi Balasubramanian
Journal:  Mol Cell Biochem       Date:  2012-09-25       Impact factor: 3.396

Review 7.  Effects of aldosterone on insulin sensitivity and secretion.

Authors:  James M Luther
Journal:  Steroids       Date:  2014-09-04       Impact factor: 2.668

Review 8.  Optimization of cardiac metabolism in heart failure.

Authors:  Tomohisa Nagoshi; Michihiro Yoshimura; Giuseppe M C Rosano; Gary D Lopaschuk; Seibu Mochizuki
Journal:  Curr Pharm Des       Date:  2011-12       Impact factor: 3.116

Review 9.  The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes.

Authors:  Thiago Bruder-Nascimento; Marcondes Ab da Silva; Rita C Tostes
Journal:  Diabetol Metab Syndr       Date:  2014-08-24       Impact factor: 3.320

10.  Clinical effects of combined treatment by optimal dose of furosemide and spironolactone on diastolic heart failure in elderly patients.

Authors:  Zhi-Hao Chen; Yu-Rong Jiang; Jia-Qin Peng; Jia-Wang Ding; Song Li; Jian Yang; Hui Wu; Jun Yang
Journal:  Exp Ther Med       Date:  2015-12-31       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.